Related Experiment Video
Updated: Feb 26, 2026
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review
A Rosso1, E Pitini1, E D'Andrea1
1Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy.
Insights
Cascade genetic screening for familial hypercholesterolemia (FH) is cost-effective. This strategy identifies individuals with FH, a genetic disorder causing high LDL-cholesterol and early heart disease, improving diagnosis and management.
Area of Science:
- Genetics
- Cardiovascular Medicine
- Health Economics
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated LDL-cholesterol, leading to premature coronary heart disease (CHD).
- Increased understanding of FH mutations and statin efficacy has spurred interest in genetic screening for improved diagnosis.
- Evaluating the cost-effectiveness of genetic screening strategies is crucial for optimizing FH diagnosis and management.
Purpose of the Study:
- To systematically review and evaluate the cost-effectiveness of genetic screening strategies for Familial hypercholesterolemia (FH).
Main Methods:
- A systematic review of full economic evaluations of FH genetic screening strategies was conducted.
- Searches were performed across multiple databases including Medline, Scopus, and Web of Science.
- Data extraction and quality assessment were performed independently by two reviewers, with findings summarized in a narrative synthesis.
Main Results:
- Seven economic evaluations published between 2002 and 2015, primarily from Europe, were included.
- Cascade screening, involving genetic testing of relatives of diagnosed FH index cases, was the most frequently assessed strategy.
- Cascade screening was found to be cost-effective in the majority of evaluated settings.
Conclusions:
- The review confirms that cascade genetic screening is a cost-effective approach for diagnosing Familial hypercholesterolemia (FH).
- Further research is warranted to assess the cost-effectiveness of cascade screening in light of new therapeutic guidelines and next-generation sequencing technologies.
Background:
Familial hypercholesterolemia (FH) is a genetic disorder that leads to elevated plasma LDL-cholesterol levels and premature coronary heart disease (CHD). An understanding of the mutations responsible for FH and the effectiveness of statins in lowering the risk of CHD in FH patients has increased interest in genetic screening strategies to improve FH diagnosis. In this study, we aimed to evaluate the cost-effectiveness of such strategies.
Methods:
We performed a systematic review of full economic evaluations that assessed the cost-effectiveness of FH genetic screening strategies. We used relevant search terms to investigate Medline, Scopus, Web of Science, the Database of Abstracts of Reviews of Effects, the Health Technology Assessment Database, and the National Health Service Economic Evaluation Database. Data extraction and assessment of the quality of the studies were performed independently by two reviewers. The key features of the included studies are summarized in a narrative synthesis.
Results:
We included seven economic evaluations that assessed the cost-effectiveness of genetic screening for FH, published mainly in Europe between 2002 and 2015. Most studies had a no-screening strategy as a comparator, focused on relatives of index cases with genetic or clinical diagnosis of FH (cascade screening), considered a lifetime horizon and adopted a health care payer viewpoint. Cascade screening, based on genetic testing of relatives of an index case with confirmed clinical or genetic diagnosis of FH, was shown to be cost-effective in most settings.
Conclusions:
Our review confirms the cost-effectiveness of cascade genetic screening for the diagnosis of FH. Further research may be needed to assess the cost-effectiveness of cascade screening following the introduction of newly recommended therapeutic regimes and next-generation sequencing.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
02:46Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:26Atherosclerosis III: Management
01:29Cholesterol: Significance and Regulation
Considering cholesterol and...
01:27Principles of Pharmacogenetics: Types of Genetic Variants